COMBORIDITY IN CHRONIC PERSISTENCE OF HERPETIC INFECTION: INTEGRATED APPROACHES TO TREATMENT OF PATIENTS
The polymorbidity of a modern patient is often associated with chronic persistence of an immunotropic infection, such as herpes types 4, 5, 6, 7. The suppression programmed by these viruses reduces the body’s overall resistance, causes the syndrome of «chronic fatigue», and suppresses anti cancer surveillance. However, the carriage of herpes virus infection is still not only not qualified as a disease, but is not considered as a risk factor for the formation of comorbid pathology requiring therapeutic containment. The purpose of the study was to justify the appointment of antiviral therapy in comorbid patients with chronic persistence of immunotropic herpes with an assessment of its effectiveness. Materials and methods. A simple open comparative study was carried out, in which patients with polymorbid pathology were included against the background of established chronic persistence of immunotropic herpes virus infection: 30 patients, often and for a long time (ill) with infectious diseases suffering from multiple chronic foci of infection (I observation group) and 30 cancer patients with stage IV of the process (observation group II). A comparative assessment of quantitative and functional indicators of subpopulations of immunocompetent cells of interferon status was carried out, the effectiveness of antiherpetic therapy with recombinant interferon preparations was evaluated. Results. All 100% comorbid patients of both observation groups showed serological signs of carriage, herpes 1, 2, 3, 4, 5, 6 (high level of specific immunoglobulins in different combinations). The immunological status is typical for group I patients, characterized by insufficiency of NK- and B-cell immunity links against the background of blood lymphocytic monocytosis. Group II patients were noted for total immunosuppression with a tendency to blood lymphopenia, which should be regarded as a sign of cancer risk in herpes virus carriage. Carrying out antiviral therapy using recombinant alpha and gamma interferons was accompanied by filling in the deficiency of the resources of the interferon system and the dynamics of restoring the balance in the immune system, which led to an improvement in the subjective well being of patients and an increase in their resistance to infection. Conclusions. It has been suggested that one of the factors of comorbid morbidity is the immunodeficiency state induced by the chronic persistence of herpes virus infection. The use of polycytokine therapy with recombinant interferon preparations improves the condition of patients and increases the effectiveness of their treatment.